AI-designed drug, ISM3091, granted US FDA IND approval
In late May, Insilico Medicine announced the recent US FDA initial IND approval of ISM3091 for the treatment of patients with solid tumors, the drug was designed with Insilico Medicine’s machine learning platform termed Chemistry42. Marking the first time that the AI-driven drug discovery company has received approval for an oncology program to progress to clinical validation testing.